BRC Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
25
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$28.5M
- Investors
-
10
BRC Therapeutics General Information
Description
Operator of a pharmaceutical firm intended for plant-based therapeutics and hemp testing. The company offers hemp and cannabis analysis for potency and contaminant testing and stability data generation, enabling researchers to find treatments related to post-traumatic stress disorder, chronic pain, and other ailments for patients and veterans.
Contact Information
Website
www.brctherapeutics.comCorporate Office
- 11045 Commercial Parkway
- Castroville, CA 95012
- United States
Corporate Office
- 11045 Commercial Parkway
- Castroville, CA 95012
- United States
BRC Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Later Stage VC (Series A) | 09-Aug-2023 | $28.5M | Completed | Clinical Trials - Phase 2 |
BRC Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
BRC Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
BRC Therapeutics Patents
BRC Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025231391-A1 | Cannabinoid compositions for treatment of aromatase inhibitor-induced arthralgia | Pending | 02-May-2024 | ||
| AU-2024407606-A1 | Cannabinoid compositions for treatment of complex regional pain syndrome | Pending | 22-Dec-2023 | ||
| EP-4827825-A1 | Cannabinoid compositions for treatment of complex regional pain syndrome | Pending | 22-Dec-2023 | ||
| WO-2025137604-A1 | Cannabinoid compositions for treatment of complex regional pain syndrome | Inactive | 22-Dec-2023 | ||
| AU-2024403831-A1 | Cannabinoid compositions for treatment of post-traumatic epilepsy | Pending | 22-Dec-2023 | A61P25/08 |
BRC Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
BRC Therapeutics Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Achari Ventures | Venture Capital | Minority | ||
| AFI Capital Partners | Growth/Expansion | Minority | ||
| Argonautic Ventures | Venture Capital | Minority | ||
| Atacama Ventures | Venture Capital | Minority | ||
| Delta Emerald Ventures | Venture Capital | Minority |
BRC Therapeutics FAQs
-
When was BRC Therapeutics founded?
BRC Therapeutics was founded in 2017.
-
Where is BRC Therapeutics headquartered?
BRC Therapeutics is headquartered in Castroville, CA.
-
What is the size of BRC Therapeutics?
BRC Therapeutics has 25 total employees.
-
What industry is BRC Therapeutics in?
BRC Therapeutics’s primary industry is Drug Discovery.
-
Is BRC Therapeutics a private or public company?
BRC Therapeutics is a Private company.
-
What is the current valuation of BRC Therapeutics?
The current valuation of BRC Therapeutics is .
-
What is BRC Therapeutics’s current revenue?
The current revenue for BRC Therapeutics is .
-
How much funding has BRC Therapeutics raised over time?
BRC Therapeutics has raised $28.5M.
-
Who are BRC Therapeutics’s investors?
Achari Ventures, AFI Capital Partners, Argonautic Ventures, Atacama Ventures, and Delta Emerald Ventures are 5 of 10 investors who have invested in BRC Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
